ࡱ> ]`\[ bjbj ^:ΐΐ.]]]]]qqq8D<q E ):c(DDDDDDD$,GID]D]]D###]]D#D##{1|2|aiq1wDD0 E 2\J` f\J$22h\J]75@#DD!< E\J #: Lipitor - Case Review Focus Blocks LIPITOR - Drug information: Lipitor is the brand name for the drug atorvastatin. Lipitor (atorvastatin) was introduced in 1996 by Warner-Lambert Company, which was subsequently acquired by Pfizer. This prescription medication is a popular drug to treat high cholesterol. It is a member of the Statin class of hypolipidemics. The FDA approved Lipitor in December of 1996. It is prescribed in 10 mg to 80 mg tablets that are taken daily. Like other Statin medications, Lipitor prevents an enzyme in the liver from creating low density lipids (LDLs). LDLs are a type of cholesterol that blocks arteries. Lipitor works to prevent the production of LDL and reduces the users risk of developing heart disease. FDA WARNING ABOUT LIPITOR: In 2012, the  HYPERLINK "http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm" \t "_blank" FDA forced label changes for Lipitor and other stations to add information to the Warnings and Precautions section about the potential link to an increased risk of diabetes. However, the Lipitor warnings added by Pfizer remain incomplete and inadequate, failing to properly warn users or the medical community about the risk of diabetes or the importance of monitoring blood glucose levels. LAWSUIT FOCUS: Development of Diabetes Skeletal Muscle Side Effects caused due to Lipitor Risk of kidney or liver damage Areas to be focused in Medical Records Review Whether the patient was prescribed Lipitor Did the patient have any preexisting conditions, allergies or contraindications for the Lipitor drug? Dosage and Intake details Critical Review of Physician Drug Prescription Details Pharmacy Dispensing Details Pharmacy Refill Details Details of Pharmacy Dispensing Details are taken as Confirmatory Did the patient develop diabetes or skeletal muscle problem after Lipitor intake? When and where was it diagnosed? Treatment/management Follow-up visits for management Outcome/prognosis Any medical/surgical history, social history (smoking) that could have had an effect on the injury Resultant Injuries: DIABETES Postmenopausal women taking Lipitor may have an increased risk of developing Lipitor Type 2 diabetes side effect. LIPITOR MIGHT CAUSE SKELETAL MUSCLE SIDE EFFECTS: According to its  HYPERLINK "http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020702s056lbl.pdf" \t "_blank" FDA-mandated drug label, Lipitor, like other Statin drugs, can cause skeletal muscle side effects such as myopathy and rhabdomyolysis, a condition characterized by atrophying skeletal muscle tissue. The lost muscle mass (myoglobin) collects in patients blood and can cause severe kidney problems and even death. Most of the time, this disease is caused by severe injury such as a muscle being crushed by a heavy object, and in other cases it arises due to extreme alcohol abuse. Primary symptoms include: Pain Tenderness Weakness Swelling The broken-down muscle mass can cause other problems throughout the body such as: Electrolytic disturbances Nausea Vomiting Confusion Coma Cardiac arrhythmia Dark urine Oligura or Anuria (decreased or non-existent urine production, respectively) Internal blood clotting Lipitor Might Cause Memory Loss Also in the February 2012 update, the FDA informed the public that it was investigating reports of Lipitor memory loss that occurred to users who had been on the drug for several years. Symptoms arose in every age group, though more often in patients over the age of 50. Examples are: Memory loss Forgetfulness Confusion Fuzzy or unfocused thinking Treatment and Complications Treatment includes rapid rehydration, as most cases of rhabdomyolysis are caused by severe accidents. Doctors may also prescribe various drugs to cause myoglobin to disintegrate. In extreme cases, theyll put patients on dialysis. Drug interactions: Later, in March 2012, the  HYPERLINK "http://www.fda.gov/Drugs/DrugSafety/ucm293877.htm" FDA warned the public that Lipitor use combined with certain other drugs, namely protease inhibitors meant to treat HIV and hepatitis C, can raise the amount of Lipitor in users blood, which can cause muscle damage. The FDA contraindicates using Crestor with these drugs. Risk for developing complication is higher if the patients are Are obese or have excess weight Are inactive Have high blood sugar Have high blood pressure Have high triglycerides Have a family history of Type 2 Diabetes Other manufacturer of generic Lipitor and its recall: Ranbaxy in November recalled its Atorvastatin from the U.S. market and stopped manufacturing the widely used cholesterol lowering medicine after the company discovered contamination with tiny glass particles in certain lots of 10 milligram, 20 mg and 40 mg doses of the drug. Atorvastatin is the generic name for Lipitor.       PAGE 1 of  NUMPAGES 3  $%'.ACDjkwy۷o`oQB0Q"hNJh~6CJOJQJ]aJhNJh~CJOJQJaJh~h~CJOJQJaJhNJ0J$>*CJOJQJaJ#hNJh~0J$>*CJOJQJaJ#hNJha0J$>*CJOJQJaJ#hNJh-0J$>*CJOJQJaJ#hNJhZ0J$>*CJOJQJaJ#hNJhd0J$>*CJOJQJaJ#hNJhl0J$>*CJOJQJaJ#hNJh0J$>*CJOJQJaJ#hNJht0J$>*CJOJQJaJ%&'Dm       $d-D9DM [$\$a$gdM$d-D9DM [$\$a$gdM$dH-DM [$a$gdM$d[$\$a$gdM$d[$\$a$gdMyM S       ;|eTC0$hNJht0JCJOJQJ^JaJ hNJh@8CJOJQJ^JaJ hNJhtCJOJQJ^JaJ-hNJhtCJOJQJaJfHq 0hNJht>*CJOJQJaJfHq 3hNJh@85>*CJOJQJaJfHq h~h,@CJOJQJaJh~h~CJOJQJaJ1hNJhtCJOJQJ^JaJfHq 1hNJh@8CJOJQJ^JaJfHq   j k     }l[I:hNJhtCJOJQJaJ"hNJht5>*CJOJQJaJ hNJh~CJOJQJ^JaJ hNJhtCJOJQJ^JaJ,hNJh@85B* CJOJQJ^JaJphp$hNJht0JCJOJQJ^JaJ0hNJh,@0J>*B*CJOJQJ^JaJph0hNJh@80J>*B*CJOJQJ^JaJph hNJh@8CJOJQJ^JaJ)jhNJh@8CJOJQJU^JaJ S r s 3NaLm,$hd^ha$gdM,$ & Fda$gdM$d[$\$a$gdM$ & Fd?-D9DM [$\$a$gdM$ & Fd[$\$a$gdM R S T r s -./78˶xq`xN<-hNJh@8CJOJQJaJ#hNJh@8>*CJOJQJ^JaJ#hNJht>*CJOJQJ^JaJ!hNJhNJ^JfHq hNJ5>*hNJhNJ5>* h/5 hNJ5hNJh/5"hNJhN/5>*CJOJQJaJhNJhN/5CJOJQJaJ)hN/hN/B*CJOJQJ^JaJph""")hNJhN/B*CJOJQJ^JaJph"""hNJhtCJOJQJaJ hNJhTTiCJOJQJ^JaJ./856PU`ir$ & Fd+9D[$\$a$gdM$d+-D9DM [$\$a$gdM$d+x-D9DM [$\$a$gdM,$d^a$gdM,$ & Fda$gdMRSjkmz46TUrs234stްϒϒρoϒ_Nް hNJht0JCJOJQJaJhNJh/5CJOJQJaJ"hNJh/5CJOJQJ\aJ hNJh/CJOJQJ^JaJhNJh/CJOJQJaJhNJh,@CJOJQJaJ=hNJh@80J>*B*CJOJQJaJeh@phr@hNJh@8CJOJQJaJ%jhNJh@8CJOJQJUaJhNJhtCJOJQJaJrsi|$d+-D9DM [$\$a$gdM$d+x-D9DM [$\$a$gdM$ & Fd+9D[$\$a$gdM$d+-D9DM [$\$a$gdM$d+9D[$\$^a$gdM  $ & Fx[$\$^a$gdM$d+-D9DM [$\$a$gdM$[$\$a$gdM$d+9D[$\$^a$gdM$ & Fd+9D[$\$a$gdMij̽udR=()hNJhN/B*CJOJQJ^JaJph)hNJhTTiB*CJOJQJ^JaJph#hNJh/0J$5CJOJQJaJ h'h#0J$CJOJQJaJ h'hNJ0J$CJOJQJaJ h'h/0J$CJOJQJaJ#hNJh#0J$5CJOJQJaJ&hNJhr0J$5CJOJQJ\aJhNJh/CJOJQJaJhNJh@8CJOJQJaJ hNJht0JCJOJQJaJ%jhNJh@8CJOJQJUaJ &?ij$[$\$a$gda$[$\$a$gda$[$\$a$gdM$ & Fx[$\$^a$gdMj}罟rjfjfjfjf\WD5hP hy&CJOJQJaJ%jhP hy&CJOJQJUaJ hy&5jhy&5Uh jh U#hNJh/0J$5CJOJQJaJ4hyv*B*CJOJQJ^JaJfHphq :hNJh/B*CJOJQJ^JaJfHphq )hNJh/B*CJOJQJ^JaJph)hNJ5>*B*CJOJQJ^JaJph/hNJh/5>*B*CJOJQJ^JaJph   IJ#hNJh/0J$5CJOJQJaJh hy&hP hy&CJOJQJaJ!hMCJOJQJaJmHnHu%jhP hy&CJOJQJUaJ $[$\$a$gdM\&P ,p .p 1h/R 5! 7! :pLF. A!8"#$% Dds (\  3 S"`s 88^1 0H02 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH N`N %#Normaldd[$\$CJ_HaJmH sH tH ZZ t Heading 1$<@&5CJ KH OJQJ\^JaJ @@"@ .%# Heading 2@&5CJ$\aJ$VV *B*ph*W * %#Strong5\4^@4 %#0 Normal (Web)8!8 %#apple-style-spanBO1B %#apple-converted-space4 `B4 %#Footer  H$F/QF %# Footer CharCJ_HaJmH sH tH NbN %# article_textB*CJOJQJaJph.q. %# mw-headlineFV F *B* ph44 7'Header  !"" taddmd ati.. a nlm_degrees.. 7W ja50-header** 7W text_bold44 7Wja50-ce-authorz]z7Wz-Bottom of Form' $$dN[$\$a$<CJOJQJ^JaJ.. 7W ja50-ce-sup</!< ?addmd1CJOJQJ^JaJo(bC2b -MBody Text Indent #8[$\$^8`CJaJ4X`A4 a@Emphasis 56\]6a Q6 a HTML Cite 6]phRbR ^Qmsolistparagraph&[$\$^jsj j Table Grid7:V'0' / 3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!Ptheme/theme/theme1.xmlYOo6w toc'vuر-MniP@I}úama[إ4:lЯGRX^6؊>$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3ڗP 1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g- eW )6-rCSj id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q%p%m&]caSl=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ.uχYC6OMf3or$5NHT[XF64T,ќM0E)`#5XY`פ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R3U~7+׸#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vpIYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07%<ҍPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Ptheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] : ---0y j r jR j 3sXXX')0!l  ,R$}I"RSm@ 0(  B S  ?RRqqRRqq.6AMSRRqq(m z i.AMSRRqq(m z i$xbQ":(%z' Y2HTNQ9ZMRtQg4{Y`j7z =nUcc! >#M#X iwm!(tVU_t )@~xi4bnq6 Z _ { < E W ^ s W1 4 : WE e t 2 g l !%#O%(hidel"XZ;8t`uR6$9?^AM *E3,KBXGo}xGd~q )F+FT)qM;?Yh NJcjO#r5j55wEVa  #!rF(@o yDU)EYfr)4 K W e!P"("xE"G"#rp#d$o3$Cd$K~$%n %S %;"%{%&r&l&y&v'$'.8'_'f'f'Z((=.(Z(n(Xo())) ))E)!)1)*H *.*N*rc*yv* +++<'+2+@+u+V+,0,`E,$-L.`Z.^.b.!/o#/;/I/N/N/'[/0z/M|/5E0}b0@O1d1f1g14C4YP4jz4a~4?5i-525OK5]5C6U6\6{ 7 7-7_7`7af7@881838{8\9*9<9F9L9@:::7:^;H<<= )=4G= >4>`>Nk>??r@$@,@.@A,AgA6+CF5CjC,D.DODTRD_DE E#E9EXE{EEFF2F9FKFqiF)yF:GE1G3GdG:iGyiGbuGvGJH_HaHuHwH I#I/IffIJJ|J>JoAJffefIg6hg{g3 hy*h-h'im(i57i @iKiTTi}xijSjokkWkhkjkzk$lHKLtws&H6?^BoDM!|P*4Wm`INe^q87{ban*3hGZN./=2?LWSTBdI-BD&-./Vzkaru473lk*0OF~m!yP(|'3IJMBapw#~ma+{Y^+ 6\k+:!:XqeemPvyQi 7_<lm2!SSh' +8DEKMMoDo "3D1y^n=ux$fmJsoy|l4>wKiud 1dDLFk)Q{} FMtK- ?+A\r4lz! )TK !#o9\rMiCXDRIU|G Q&B`ozz}3E6?@^{rH.`1Rw2u5P*<4xYUzG`xHF#u7@#:_r,^Qc<jz#|#Vli |/~``$&76S 7'.Dxbij,5adtp$A CDdu"'n:TUW>Dhttp://www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm<  !"#$%'()*+,-./0123456789:;<=>?@ABCDEFGHIJKMNOPQRSUVWXYZ[^_jbcdefghiRoot Entry FףiaData 1Table&JWordDocument^:SummaryInformation(LDocumentSummaryInformation8TMacros aiaiVBA aiaidirThisDocument _VBA_PROJECTPROJECT ;F  !"#$%&'()*+,-./0123456789:<=>?@C0* pHdProjectQ(@= l M J< rstdole>stdoleP h%^*\G{00020430-C 0046}#2.0#0#C:\WINDOWS\system32\e2.tlb#OLE Automation`ENormalENCrmaQF  *\C m! OfficgOficg!G{2DF8D04C-5BFA-101B-BHDE5gAAe4 2ggram Files\C ommonMicrosoft Shared\OFFICE12\MSO.DLL#M 1 Ob Library%z%BeThisDocumenPtG TfisDHcuQ@Ienn 2E HB1BB,!+y"B+BB%+yxME (S"SS"<(1Normal.ThisDocument8(%HxAttribute VB_Name = "ThisDocument" Bas1Normal.VGlobal!SpaclFalse CreatablPre declaIdTru BExposeTemplateDeriv$Custom izC1a  *\G{000204EF-0000-0000-C000-000000000046}#4.0#9#C:\PROGRA~1\COMMON~1\MICROS~1\VBA\VBA6\VBE6.DLL#Visual Basic For Applications*\G{00020905-0000-0000-C000-000000000046}#8.4#0#C:\Program Files\Microsoft Office\Office12\MSWORD.OLB#Microsoft Word 12.0 Object Library*\G{00020430-0000-0000-C000-000000000046}#2.0#0#C:\WINDOWS\system32\stdole2.tlb#OLE Automation*\CNormal*\CNormalM(*\G{2DF8D04C-5BFA-101B-BDE5-00AA0044DE52}#2.4#0#C:\Program Files\Common Files\Microsoft Shared\OFFICE12\MSO.DLL#Microsoft Office 12.0 Object Library M %ThisDocument034de7e5c4ThisDocument+y fP8B0eN` %WordkVBAWin16~Win32MacVBA6#Project1 stdole`Project- ThisDocument< _EvaluateNormalOfficeuDocumentjT ID="{72F2AE69-ECB5-4DE9-A2F2-F4DAA6147113}" Document=ThisDocument/&H00000000 Name="Project" HelpContextID="0" VersionCompatible32="393222000" CMG="5D5F5435EC96F096F096F096F0" DPB="BAB8B39C119D119D11" GC="17151E4326FD82FE82FE7D" [Host Extender Info] &H00000001={3832D640-CF90-11CF-8E43-00A0C911005A};VBE;&H00000000 ThisDocumentThisDocument  F'Microsoft Office Word 97-2003 Document MSWordDocWord.Document.89qPROJECTwmA)CompObjBy